Systemic effects of intravitreal vascular endothelial growth factor inhibitors

Current Opinion in Ophthalmology

Volumn 24, Issue 3, 2013, Pages 197-204

  Campbell, Robert J ^a,b,c   Bell, Chaim M ^c,d,e,f   Campbell, Erica De L P ^a,b   Gill, Sudeep S ^b,g,h  

^a HOTEL DIEU HOSPITAL   (Canada)

^b Hotel Dieu and Kingston General Hospitals   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d Department of Medicine ^*  (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h St Mary's of the Lake Hospital   (Canada)

Author keywords

Adverse Events; Aflibercept; Bevacizumab; Ranibizumab; Vascular Endothelial Growth Factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

ARTERIAL THROMBOEMBOLISM; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; DIABETIC MACULAR EDEMA; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; EYE DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK;

ANGIOGENESIS INHIBITORS; DRUG TOXICITY; HUMANS; INTRAVITREAL INJECTIONS; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876289699     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835f8bbe     Document Type: Review

References (50)

1. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008; 115:1837-1846.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431.
4. Research Group CATT, Martin D, Maguire M, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897-1908. A pivotal clinical trial comparing ranibizumab and bevacizumab with important safety data.
5. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117:1102; 12e1.
6. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118:609-614.
7. Kamba T, McDonald D. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788.
8. Tunó n J, Ruiz-Moreno JM, Martín-Ventura JL, et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 2009; 54:339-348.
9. Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009; 4:67-76.
10. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009; 148:647-656.
11. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239.
12. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29:632-638.
13. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277.
14. Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010; 79:27-38.
15. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
16. Werther W, Chu L, Holekamp N, et al. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol 2011; 129:326-331.
17. Sun C, Klein R, Wong TY. Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology 2009; 116:1913-1919.
18. Nguyen-Khoa BA, Goehring EL Jr., Werther W, et al. Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol 2008; 126:1280-1286.
19. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2003; 110:636-643.
20. Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007; 114:2174-2178.
21. Duan Y, Mo J, Klein R, et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007; 114:732-737.
22. Wong TY, Klein R, Sun C, et al. Age-related macular degeneration and risk for stroke. Ann Intern Med 2006; 145:98-106.
23. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010; 340:c2459.
24. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124:1532-1542.
25. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116:1731-1739.
26. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012; 119:1175-1183.
27. Schmucker C, Loke YK, Ehlken C, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011; 95:308-317. A meta-analysis of intravitreal VEGF inhibitor safety.
28. Schmucker C, Ehlken C, Agostini HT, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard. PLoS One 2012; 7:e42701. A meta-analysis of intravitreal VEGF inhibitor safety.
29. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239-248.
30. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009; 116:362. A meta-analysis of intravitreal ranibizumab safety.
31. Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012; 32:1821-1828. Pooled data analysis of ranibizumab safety.
32. Research Group CATT, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388-1398. Two-year data from pivotal clinical trial comparing ranibizumab and bevacizumab with important safety data.
33. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119:1399-1411. A pivotal clinical trial comparing ranibizumab and bevacizumab with important safety data. It includes meta-analysis combining data from IVAN and CATT.
34. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128:1273-1279. Large population-based safety study.
35. French DD, Margo CE. Age-related macular degeneration, antivascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. Retina 2011; 31:1036-1042. A large population-based safety study.
36. Campbell RJ, Gill SS, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012; 345:e4203. A large population-based safety study.
37. Campbell RJ, Bell CM, Paterson JM, et al. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. Ophthalmology 2012; 119:1604-1608. A large population-based safety study.
38. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119:789-801.
39. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118:615-625.
40. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117:1124; 33 e1.
41. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119:802-809.
42. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130:972-979.
43. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116:1142-1150.
44. Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights 2012; 6:19-30.
45. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012; 119:1024-1032.
46. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119:2537-2548.
47. Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 2012; 12:1299-1313.
48. Davis J, Olsen TW, Stewart M, Sternberg P Jr. How the comparison of agerelated macular degeneration treatments trial results will impact clinical care. Am J Ophthalmol 2011; 152:509-514.
49. Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007; 356:747-748.
50. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments. JAMA 2008; 300:2417-2419.